KELLY WEITZ: Open Payments
NPI 1881932481 · RALEIGH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$558 in 27 payments from 11 companies in 2025. Trend: 2023 $499 · 2024 $653 · 2025 $558
Food & beverage: $558
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $127 |
| Gilead Sciences, Inc. | 3 | $83 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| ABBVIE INC. | 3 | $58 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Lilly USA, LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Exact Sciences Corporation | 1 | $19 |
Products named: Wegovy, AIRSUPRA, CAPLYTA, VRAYLAR, SHINGRIX, REXULTI, Rybelsus, Auvelity.
Industry payments across NC — which companies pay providers there.
